Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinking

Blood

Volumn 126, Issue 16, 2015, Pages 1940-1948

  Byrnes, James R ^a   Duval, Cédric ^b   Wang, Yiming ^c   Hansen, Caroline E ^d,e,f   Ahn, Byungwook ^d,e,f   Mooberry, Micah J ^a   Clark, Martha A ^a   Johnsen, Jill M ^g,h   Lord, Susan T ^a   Lam, Wilbur A ^d,e,f   Meijers, Joost C M ^i,j   Ni, Heyu ^c   Ariëns, Robert A S ^b   Wolberg, Alisa S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^e Emory University   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Research Institute   (United States)

^h UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF AMSTERDAM   (Netherlands)

^j SANQUIN RESEARCH   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 13A; FIBRIN; FIBRIN ALPHA; FIBRONECTIN; GLUTAMINE; LYSINE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; UNCLASSIFIED DRUG; ALPHA 2 ANTIPLASMIN; BLOOD CLOTTING FACTOR; GAMMA GLUTAMYLTRANSFERASE;

ANIMAL CELL; ARTICLE; ASSAY; BLOOD CLOT; ERYTHROCYTE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; ANIMAL; BLEEDING DISORDER; BLOOD CLOTTING; DEFICIENCY; GENETICS; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY;

ALPHA-2-ANTIPLASMIN; ANIMALS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; CARBOXYPEPTIDASE B2; ERYTHROCYTES; FIBRONECTINS; GAMMA-GLUTAMYLTRANSFERASE; HEMORRHAGIC DISORDERS; HUMANS; MICE; MICE, KNOCKOUT;

EID: 84944200239     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-06-652263     Document Type: Article

References (52)

1. Lord ST. Molecular mechanisms affecting fibrin structure and stability. Arterioscler Thromb Vasc Biol. 2011; 31(3): 494-499.
2. Lak M, Keihani M, Elahi F, Peyvandi F, Mannucci PM. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol. 1999; 107(1): 204-206.
3. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984; 311(8): 501-505.
4. Kamphuisen PW, Eikenboom JC, Vos HL, et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost. 1999; 81(5): 680-683.
5. Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briët E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms-The Leiden Thrombophilia Study (LETS). Thromb Haemost. 1994; 71(6): 719-722.
6. Muszbek L, Bereczky Z, Bagoly Z, Komáromi I, Katona É. Factor XIII: A coagulation factor with multiple plasmatic and cellular functions. Physiol Rev. 2011; 91(3): 931-972.
7. Schroeder V, Kohler HP. Factor XIII deficiency: An update. Semin Thromb Hemost. 2013; 39(6): 632-641.
8. Ryan EA, Mockros LF, Weisel JW, Lorand L. Structural origins of fibrin clot rheology. Biophys J. 1999; 77(5): 2813-2826.
9. Hethershaw EL, Cilia La Corte AL, Duval C, et al. The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis. J Thromb Haemost. 2014; 12(2): 197-205.
10. Glover CJ, McIntire LV, Brown CH III, Natelson EA. Rheological properties of fibrin clots. Effects of fibrinogen concentration, Factor XIII deficiency, and Factor XIII inhibition. J Lab Clin Med. 1975; 86(4): 644-656.
11. Collet JP, Shuman H, Ledger RE, Lee S, Weisel JW. The elasticity of an individual fibrin fiber in a clot. Proc Natl Acad Sci USA. 2005; 102(26): 9133-9137.
12. Liu W, Jawerth LM, Sparks EA, et al. Fibrin fibers have extraordinary extensibility and elasticity. Science. 2006; 313(5787): 634.
13. Liu W, Carlisle CR, Sparks EA, Guthold M. The mechanical properties of single fibrin fibers. J Thromb Haemost. 2010; 8(5): 1030-1036.
14. Ryan EA, Mockros LF, Stern AM, Lorand L. Influence of a natural and a synthetic inhibitor of factor XIIIa on fibrin clot rheology. Biophys J. 1999; 77(5): 2827-2836.
15. Standeven KF, Carter AM, Grant PJ, et al. Functional analysis of fibrin gamma-chain crosslinking by activated factor XIII: Determination of a cross-linking pattern that maximizes clot stiffness. Blood. 2007; 110(3): 902-907.
16. Helms CC, Ariëns RA, Uitte de Willige S, Standeven KF, Guthold M. a-A Cross-links increase fibrin fiber elasticity and stiffness. Biophys J. 2012; 102(1): 168-175.
17. Duval C, Allan P, Connell SD, Ridger VC, Philippou H, Ariëns RA. Roles of fibrin a-And g-chain specific cross-linking by FXIIIa in fibrin structure and function. Thromb Haemost. 2014; 111(5): 842-850.
18. Aleman MM, Byrnes JR, Wang JG, et al. Factor XIII activity mediates red blood cell retention in venous thrombi. J Clin Invest. 2014; 124(8): 3590-3600.
19. Wolberg AS, Allen GA, Monroe DM, Hedner U, Roberts HR, Hoffman M. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. Br J Haematol. 2005; 131(5): 645-655.
20. Campbell RA, Overmyer KA, Selzman CH, Sheridan BC, Wolberg AS. Contributions of extravascular and intravascular cells to fibrin network formation, structure, and stability. Blood. 2009; 114(23): 4886-4896.
21. Tung CH, Ho NH, Zeng Q, et al. Novel factor XIII probes for blood coagulation imaging. ChemBioChem. 2003; 4(9): 897-899.
22. Lijnen HR, Okada K, Matsuo O, Collen D, Dewerchin M. Alpha2-Antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. Blood. 1999; 93(7): 2274-2281.
23. te Velde EA, Wagenaar GT, Reijerkerk A, et al. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombinactivatable fibrinolysis inhibitor. J Thromb Haemost. 2003; 1(10): 2087-2096.
24. Wang Y, Reheman A, Spring CM, et al. Plasma fibronectin supports hemostasis and regulates thrombosis. J Clin Invest. 2014; 124(10): 4281-4293.
25. Clark MA, Goheen MM, Fulford A, et al. Host iron status and iron supplementation mediate susceptibility to erythrocytic stage Plasmodium falciparum. Nat Commun. 2014; 5: 4446.
26. Lord ST, Binnie CG, Hettasch JM, Strickland E. Purification and characterization of recombinant human fibrinogen. Blood Coagul Fibrinolysis. 1993; 4(1): 55-59.
27. Gorkun OV, Henschen-Edman AH, Ping LF, Lord ST. Analysis of A alpha 251 fibrinogen: The alpha C domain has a role in polymerization, albeit more subtle than anticipated from the analogous proteolytic fragment X. Biochemistry. 1998; 37(44): 15434-15441.
28. Rampling MW. The binding of fibrinogen and fibrinogen degradation products to the erythrocyte membrane and its relationship to haemorheology. Acta Biol Med Ger. 1981; 40(4-5): 373-378.
29. Maeda N, Seike M, Kume S, Takaku T, Shiga T. Fibrinogen-induced erythrocyte aggregation: Erythrocyte-binding site in the fibrinogen molecule. Biochim Biophys Acta. 1987; 904(1): 81-91.
30. Lominadze D, Dean WL. Involvement of fibrinogen specific binding in erythrocyte aggregation. FEBS Lett. 2002; 517(1-3): 41-44.
31. Dutton A, Singer SJ. Crosslinking and labeling of membrane proteins by transglutaminasecatalyzed reactions. Proc Natl Acad Sci USA. 1975; 72(7): 2568-2571.
32. Lorand L, Shishido R, Parameswaran KN, Steck TL. Modification of human erythrocyte ghosts with transglutaminase. Biochem Biophys Res Commun. 1975; 67(3): 1158-1166.
33. Lorand L, Chenoweth D, Gray A. Titration of the acceptor cross-linking sites in fibrin. Ann N Y Acad Sci. 1972; 202: 155-171.
34. Zhou Z, Thiagarajan P, Udden M, Lòpez JA, Guchhait P. Erythrocyte membrane sulfatide plays a crucial role in the adhesion of sickle erythrocytes to endothelium. Thromb Haemost. 2011; 105(6): 1046-1052.
35. Collet JP, Moen JL, Veklich YI, et al. The alphaC domains of fibrinogen affect the structure of the fibrin clot, its physical properties, and its susceptibility to fibrinolysis. Blood. 2005; 106(12): 3824-3830.
36. Kurniawan NA, Grimbergen J, Koopman J, Koenderink GH. Factor XIII stiffens fibrin clots by causing fiber compaction. J Thromb Haemost. 2014; 12(10): 1687-1696.
37. Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev. 2007; 21(3): 131-142.
38. Aleman MM, Walton BL, Byrnes JR, et al. Elevated prothrombin promotes venous, but not arterial, thrombosis in mice. Arterioscler Thromb Vasc Biol. 2013; 33(8): 1829-1836.
39. Machlus KR, Lin FC, Wolberg AS. Procoagulant activity induced by vascular injury determines contribution of elevated factor VIII to thrombosis and thrombus stability in mice. Blood. 2011; 118(14): 3960-3968.
40. Machlus KR, Cardenas JC, Church FC, Wolberg AS. Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. Blood. 2011; 117(18): 4953-4963.
41. Elgue G, Sanchez J, Fatah K, Olsson P, Blombäck B. The effect of plasma antithrombin concentration on thrombin generation and fibrin gel structure. Thromb Res. 1994; 75(2): 203-212.
42. Konieczynska M, Fil K, Bazanek M, Undas A. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis. Thromb Haemost. 2014; 111(4): 685-693.
43. Gronostaj K, Richter P, Nowak W, Undas A. Altered plasma fibrin clot properties in patients with digestive tract cancers: Links with the increased thrombin generation. Thromb Res. 2013; 131(3): 262-267.
44. Wolberg AS, Monroe DM, Roberts HR, Hoffman M. Elevated prothrombin results in clots with an altered fiber structure: A possible mechanism of the increased thrombotic risk. Blood. 2003; 101(8): 3008-3013.
45. De Oliveira S, Vitorino de Almeida V, Calado A, Rosário HS, Saldanha C. Integrin-Associated protein (CD47) is a putative mediator for soluble fibrinogen interaction with human red blood cells membrane. Biochim Biophys Acta. 2012; 1818(3): 481-490.
46. Carvalho FA, Connell S, Miltenberger-Miltenyi G, et al. Atomic force microscopy-based molecular recognition of a fibrinogen receptor on human erythrocytes. ACS Nano. 2010; 4(8): 4609-4620.
47. Franco RS, Puchulu-Campanella ME, Barber LA, et al. Changes in the properties of normal human red blood cells during in vivo aging. Am J Hematol. 2013; 88(1): 44-51.
48. Nikolajsen CL, Dyrlund TF, Poulsen ET, Enghild JJ, Scavenius C. Coagulation factor XIIIa substrates in human plasma: Identification and incorporation into the clot. J Biol Chem. 2014; 289(10): 6526-6534.
49. Cines DB, Lebedeva T, Nagaswami C, et al. Clot contraction: Compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin. Blood. 2014; 123(10): 1596-1603.
50. Liang XM, Han SJ, Reems JA, Gao D, Sniadecki NJ. Platelet retraction force measurements using flexible post force sensors. Lab Chip. 2010; 10(8): 991-998.
51. Lam WA, Chaudhuri O, Crow A, et al. Mechanics and contraction dynamics of single platelets and implications for clot stiffening. Nat Mater. 2011; 10(1): 61-66.
52. Wolberg AS, Rosendaal FR, Weitz JI, et al. Venous thrombosis. Nature Rev Dis Primers. 2015; 1: Article 15006. doi: 10.1038/nrdp.2015.6.